The FDA has even authorized a drug designed with cannabidiol for that goal (Epidiolex). Nevertheless the agency only endorses it for two rare forms of childhood epilepsy called Lennox-Gastaut syndrome and Dravet syndrome.In 2024, the U.S. Drug Enforcement Administration (DEA) indicated they plan to reclassify marijuana for a Schedule III drug. This